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Abstract
Pre-B-cell leukemia transcription factor 1 (PBX1), which is located on chromosome 1q23, was recently reported to be associated with type 2
diabetes mellitus. We examined whether single nucleotide polymorphisms (SNPs) of the PBX1 gene are associated with overweight/obesity in a
Korean population. We genotyped 66 SNPs in the PBX1 gene and investigated their association with clinical phenotypes found in 214 overweight/obese
subjects and 160 control subjects using the Affymetrix Targeted Genotyping chip array. Seven SNPs (g.+75186C>T, g.+78350C>A, g.+80646C>T,
g.+138004C>T, g.+185219G>A, g.+191272A>C, and g.+265317T>A) were associated with the risk of obesity in three models (codominant, dominant,
and recessive) (P=0.007-0.05). Haplotype 1 (CAC) and 3 (TAC) of block 3 and haplotype 2 (GGAAT) of block 10 were also strongly associated 
with the risk of obesity. In the control group, subjects that had homozygote for the major allele for both g.+185219G>A and g.+191272A>C showed
lower high density lipoprotein-cholesterol (HDL-C) level compared to those possessing the minor allele, suggesting that the association  between
the homozygote for the major allele for both g.+185219G>A and g.+191272A>C and HDL-C is attributable to the increased risk of obesity. This 
study suggests that the PBX1 gene is a possible risk factor in overweight/obese patients.
Key Words: High-density lipoprotein-cholesterol, overweight/obesity, Pre-B-cell leukemia transcription factor 1 (PBX1), single nucleotide 
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Introduction15)
Obesity is one of the most common disorders in clinical 
practice and closely associated with a number of pathological 
diseases, such as non-insulin-dependent diabetes, hypertension, 
and atherosclerosis (Gregoire et al., 1998). Although rare, obesity 
can be caused by mutations in a single gene. However, the 
greatest proportion of obesity involves the interaction variants 
in multiple genes with environmental factors, particularly diet 
(Loos & Bouchard, 2003; Loss & Rankinen, 2005). In addition, 
several lines of studies suggested a close association between 
insulin signaling and obesity. Kadowaki et al. (2003) have 
reported the molecular mechanisms of insulin resistance and 
obesity, focusing on the function of adipocyte.
Pre-B-cell leukemia transcription factor (PBX1) is a member 
of a ubiquitous class of homeodomain proteins. The PBX1 gene, 
localized on chromosome 1q23, was originally identified by its 
involvement in a t (1;19) chromosomal translocation in acute 
pre-B-cell leukemias
  (Kamps, 1990; Nourse et al., 1990). 
Subsequent study has shown that PBX1 is widely expressed and 
acts as a cofactor for a variety of HOX proteins
  (Sagerstrom, 
2004). These homeodomain transcription factors in turn regulate 
developmental gene expression and early embryonic development 
and organogenesis, and maintain differentiated cell states
 
(Sagerstrom, 2004).
The role of PBX1 has been well studied in the pancreas, where 
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Table 1. Clinical characteristics of study subjects
　 Control (n=160) Case (n=214) P
Age (year)  43.7 ± 6.2  44.8 ± 6.4   0.087
BMI (kg/m
2)  21.1 ± 1.2  25.6 ± 2.0 < 0.001
SBP (mmHg) 115.4 ± 16.1 124.1 ± 17.6 < 0.001
DBP (mmHg)  71.9 ± 10.3  77.8 ± 11.3 < 0.001
Fasting plasma glucose (mg/dl)  89.8 ± 11.5  93.8 ± 14.7   0.006
HbA1c (%)   5.3 ± 0.4   5.5 ± 0.7   0.028
Triglyceride (mg/dl)  97.5 ± 56.7 140.3 ± 117.2 < 0.001
Total cholesterol (mg/dl) 186.4 ± 30.0 197.2 ± 34.3   0.002
HDL-C (mg/dl)  56.9 ± 13.1  49.8 ± 11.3 < 0.001
LDL-C (mg/dl) 109.4 ± 28.8 119.3 ± 32.5   0.002
Data  expressed  as  mean ± SD.
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
HbA1c,  hemoglobin  A1c;  HDL-C,  high-density  lipoprotein  cholesterol;  LDL-C, 
low-density  lipoprotein  cholesterol;  n,  number;  P,  P-value;  case,  overweight  and 
obese  subjects.
it complexes with and regulates the key β-cell homeobox protein, 
PDX1 (IPF1 in humans)
  (Wang  et al., 2005). In mice, PDX1 
activity was sufficient for the development of the major cell 
types, but PBX1:PDX1 complex was essential for the expansion 
of each cell type within the developing pancreas, and hence for 
normal pancreatic development
  (Dutta et al., 2001). Dutta et al.
 
(2001) also suggested that PBX1:PDX1 heterodimer contributes 
to ductal cell proliferation and subsequent islet regeneration. Kim 
et al.
  (2002) examined pancreatic Pbx1 expression, morphogenesis, 
cell differentiation, and function in mice deficient for Pbx1. Pbx1 
-/- embryos had pancreatic hypoplasia and marked defects in 
exocrine and endocrine cell differentiation prior to death at 
embryonic day 15 or 16. Pbx1 +/- adults had pancreatic islet 
malformations, impaired glucose tolerance, and hypoinsulinemia. 
Consequently, Kim et al.
  (2002) concluded that PBX1 is essential 
for normal pancreatic development and function and perturbation 
of PBX1 activity may also promote susceptibility to diabetes 
mellitus.
Despite potentially important roles in metabolic diseases, 
genetic association of PBX1 on obesity is not yet unknown in 
humans. Therefore, we examined whether PBX1 polymorphism 
contributes to the susceptibility to obesity or obesity-related 
metabolism traits in a Korean population.
Materials and methods
Study subjects
The body mass index (BMI) was calculated from height and 
weight using the formula: BMI=body weight/(height)
2 in kg/m
2. In 
the World Health Organization guidelines for Asians, individuals 
with a BMI≥23 kg/m
2 are classified as overweight and those 
with a BMI≥25 kg/m
2 are defined as obese
  (World Health 
Organization Expert Consultation, 2004). We recruited a case 
group (n=214) that comprised overweight and obese subjects 
(BMI≥23 kg/m
2, 123 men and 91 women) and control subjects 
(n=160) with normal weight (BMI: 18.0-22.9 kg/m
2, 66 men and 
94 women) at Kyung Hee University Medical Center and Keimyung 
University Dongsan Medical Center. All of the subjects were 
ethnic Koreans. Blood samples were drawn for biochemical 
measurements, i.e., fasting plasma glucose, hemoglobin A1c 
(HbA1c), triglyceride (TG), total cholesterol, high-density 
lipoprotein cholesterol (HDL-C), and low-density lipoprotein 
cholesterol (LDL-C). The clinical characteristics of the subjects 
were summarized (Table 1). DNA was isolated from peripheral 
blood leukocytes using the G-DEX™  IIb Genomic DNA 
Extraction Kit (iNtRON Biotechnology, Seongnam, Korea). All 
of the subjects gave written informed consent before entering 
the study. This study was approved by the Institutional Review 
Board of Kyung Hee University Medical Center. 
Determination of genotype
Initially, we selected 66 single nucleotide polymorphisms 
(SNPs) within the PBX1 gene using the following criteria: (1) 
consisting only of SNPs in introns (approximately 300bp from 
the exon to consider alternative splicing); (2) tagging SNPs 
selected using the tagging option of the program Tagger 
(http://www.broad.mit.edu/mpg/tagger/); (3) known heterozygosity 
and minor allele frequency (MAF) > 0.05; and (4) reported 
validation (http://www.hapmap.org). The genotyping was performed 
using the Affymetrix Targeted Genotyping Chip array (Affymetrix, 
CA, USA), according to the manufacturer’s protocol. This chip 
uses molecular inversion probe technology with gene chip 
universal microarrays to provide a method that is capable of 
analyzing thousands of variants in a single reaction. In brief, 
DNA was digested and then subjected to PCR using primers 
specific to the adaptor sequence. PCR products were purified 
and the fragmented DNA was then end-labeled with biotin using 
terminal deoxynucleotidyl transferase. Labeled DNA was then 
hybridized onto the Mapping Array. The hybridized array was 
washed, stained, and scanned according to the manufacturer's 
instructions. The image was analyzed using GCOS software 
(Affymetrix). 
Statistical analysis
For the case-control association study, Hardy-Weinberg equilibrium 
(HWE) for all SNPs was assessed using SNPstats.
  (Solé et al., 
2006) A linkage disequilibrium (LD) block of polymorphisms 
was tested using Haploview (version 3.32) (MA, USA).
  (Barrett 
et al., 2005) Multiple logistic regression models were calculated 
for the odds ratio (OR), 95% confidence interval (CI) and 
corresponding  P values, controlling for age and gender as 
covariables. We used SNPstats, HapAnalyzer version 1.0 (Seoul, 
Korea)
  (Park  et al., 2008) and SNPanalyzer (ISTECH Inc., 
Goyang, Korea). The power of the sample size was calculated 
using a genetic power calculator (http://pngu.mgh.harvard.edu/~ Ju Yeon Ban et al. 291
Table 2. Association between polymorphisms in PBX1 and the risk of obesity
Locus Genotype Case Control
Codominant 　 Dominant 　 Recessive
OR (95% CI) P 　 OR (95% CI) P 　 OR (95% CI) P
g.+75186C>T CC  73 (34.6%)  39 (24.5%)
(rs2792249) CT  94 (44.5%)  85 (53.5%) 1.29 (0.96-1.73) 0.1 1.68 (1.05 - 2.69) 0.029* 1.13 (0.68 - 1.89) 0.64
TT  44 (20.9%)  35 (22.0%)
g.+78350C>A CC  70 (32.7%)  56 (35.2%)
(rs1617837) CA  97 (45.3%)  84 (52.8%) 0.75 (0.56-1.02) 0.07 0.88 (0.56 - 1.36) 0.56 0.46 (0.25 - 0.83) 0.007*
AA  47 (22.0%)  19 (11.9%)
g.+80646C>T CC 123 (57.7%) 108 (67.5%)
(rs16833488) CT  79 (37.1%)  50 (31.3%) 0.61 (0.41-0.89) 0.01* 0.63 (0.41 - 0.98) 0.038* 0.19 (0.04 - 0.91) 0.016*
TT  11 (5.2%)   2 (1.3%)
g.+138004C>T CC  72 (33.6%)  58 (36.3%)
(rs2171692) CT 114 (53.3%)  68 (42.5%) 1.13 (0.84-1.52) 0.43 0.92 (0.59 - 1.42) 0.69 1.75 (1.00 - 3.05) 0.05*
TT  28 (13.1%)  34 (21.3%)
g.+185219G>A GG 132 (63.5%)  81 (52.3%)
(rs11581537) GA  72 (34.6%)  66 (42.6%) 1.51 (1.03-2.21) 0.034* 1.49 (0.97 - 2.29) 0.07 2.74 (0.79 - 9.50) 0.1
AA   4 (1.9%)   8 (5.2%)
g.+191272A>C AA 176 (82.2%) 117 (74.1%)
(rs12068276) AC  38 (17.8%)  39 (24.7%) 1.68 (1.04-2.72) 0.035* 1.62 (0.98 - 2.67) 0.06 - 0.06
CC   0 (0.0%)   2 (1.3%)
g.+265317T>A TT 149 (69.6%) 116 (72.5%)
(rs12134242) TA  56 (26.2%)  43 (26.9%) 0.78 (0.52-1.17) 0.23 0.87 (0.55 - 1.38) 0.55 0.14 (0.02 - 1.12) 0.020*
　 AA   9 (4.2%)   1 (0.6%) 　　 　 　 　 　 　 　
Genotype distributions are shown as number (%). Odds ratio (OR), 95% confidence interval (CI), and P-values were from logistic regression analyses with the codominant, 
dominant,  and  recessive  models  controlling  age  and  gender  as  covariates.  SNP,  single  nucleotide  polymorphism;  case,  overweight a n d  o b e s e  s u b j e c t s ; P ,  P-value
purcell/gpc)
  (Purcell et al., 2003). To reduce experimental error, 
the effective sample size was adjusted (calculated sample 
size×100/95). We calculated sample powers for the SNPs to confirm 
the effects. To account for multiple testing, the Bonferroni 
method was used
  (Bland & Altman, 1995), giving a significance 
level of α/κ=0.00076 for each test. 
Clinical characteristics were compared between control and 
case subjects, using Student’s unpaired t-test for continuous 
variables with normal distribution including systolic blood 
pressure (SBP), diastolic blood pressure (DBP), fasting plasma 
glucose, HbA1c, TG, total cholesterol, HDL-C, and LDL-C. In 
addition, the statistical significance of association between the 
genetic variants and clinical characteristics in both the control 
and case groups was assessed using one-way analysis of variance 
(ANOVA) with subsequent Tukey’s tests. For all of the statistical 
tests, the level of significance was set at 0.05. 
Results
All of the measured clinical characteristics differed significantly 
between the case and control groups (Table 1). We analyzed the 
association between each genotype and susceptibility to obesity 
using logistic regression analysis, after adjusting for age and 
gender. The genotype distributions of all SNPs selected were in 
Hardy-Weinberg equilibrium (P>0.05). Of these, seven SNPs 
(g.+75186C>T, g.+78350C>A, g.+80646C>T, g.+138004C>T. 
g.+185219G>A, g.+191272A>C, and g.+265317T>A) were 
significantly associated with the risk of obesity (P<0.05; Table 2). 
The minor allele of g.+75186C>T, g.+138004C>T, g.+185219G>A, 
and g.+191272A>C had a protective effect in the dominant (P
=0.029, OR=1.68, 95% CI=1.05-2.69), recessive (P=0.05, 
OR=1.75, 95% CI=1.00-3.05), codominant (P=0.034, OR=1.51, 
95% CI=1.03-2.21), codominant (P=0.035, OR=1.68, 95 % 
CI=1.04-2.72) models, respectively. Conversely, the minor allele 
of g.+78350C>A and g.+265317T>A showed susceptibility to 
the risk of obesity when a recessive model was applied (P=0.007, 
OR=0.46, 95% CI=0.25-0.83, and P=0.02, OR=0.14, 95% 
CI=0.02-1.12, respectively). In addition, g.+80646C>T was 
statistically associated with obesity in all models. However, this 
association disappeared after correcting for multiple testing by 
the Bonferroni test.
Fifteen LD blocks in PBX1 were constructed using the Gabriel 
method.
  (Gabriel et al., 2002) Of these blocks, six LD blocks 
containing seven significant SNPs were used for further 
haplotype association analysis. Haplotypes 1 (CAC) and 3 (TAC) 
of block 3, which consisted of g.+80646C>T, g.+87440A>G, and 
g.+91850C>T, showed a significant association with obesity in 
the dominant (P=0.007, OR=0.45, 95% CI=0.26-0.81) and 
codominant (P=0.027, OR=1.54, 95% CI=1.05-2.25) models, 
respectively (Table 3). Haplotype 2 (GGAAT) of block 10, which 
comprised of g.+185286G>A, g.+185602G>A, g.+191125A>G, 
g.+191272A>C, and g.+194899G>T, was also significantly 
associated with the risk of obesity in the codominant (P=0.029, 292 SNPs of PBX1 and overweight/obesity
Table 3. Association between haplotypes of PBX1 and the risk of obesity
Block 
No.
Haplotype 
Case Control  Codominant  Dominant  Recessive 
H/H H/-  -/-  　 H/H H/-  -/-  　OR (95% CI)  P 　OR (95% CI)  P 　OR (95% CI)  P
2 1 (AT)  45 (21.0%)  93 (43.5%)  76 (35.5%)  34 (21.3%)  83 (51.9%)  43 (26.9%) 0.84 (0.63-1.12)  0.24 0.67 (0.43-1.04)  0.08 0.99 (0.60-1.63) 0.96
2 (GC)  46 (21.5%)  98 (45.8%)  70 (32.7%)  23 (14.4%)  91 (56.9%)  46 (28.8%) 1.07 (0.79-1.44)  0.66 0.83 (0.53-1.30)  0.41 1.63 (0.94-2.82) 0.08
3 (AC)   5 (2.3%)  43 (20.1%) 166 (77.6%)   1 (0.6%)  26 (16.3%) 133 (83.1%) 1.45 (0.90-2.34)  0.12 1.42 (0.84-2.40)  0.19 3.80 (0.44-32.88) 0.22
3 1 (CAC)  71 (33.2%)  94 (43.9%)  49 (22.9%)  53 (33.1%)  88 (55.0%)  19 (11.9%) 0.80 (0.59-1.07)  0.14 0.45 (0.26-0.81)  0.007* 1.00 (0.65-1.55) 0.99
2 (CGT)  11 (5.1%)  68 (31.8%) 135 (63.1%)   5 (3.1%)  58 (36.3%)  97 (60.6%) 0.99 (0.69-1.41)  0.94  0.90 (0.59-1.37)  0.63 1.68 (0.57-4.93) 0.35
3 (TAC)  11 (5.1%)  78 (36.4%) 125 (58.4%)   2 (1.3%)  50 (31.3%) 108 (67.5%) 1.54 (1.05-2.25)  0.027* 1.48 (0.96-2.27)  0.07 4.28 (0.94-19.59) 0.06
6 1 (CAC)  63 (29.4%) 115 (53.7%)  36 (16.8%)  51 (31.9%)  70 (43.8%)  39 (24.4%) 1.11 (0.83-1.48)  0.49 1.59 (0.96-2.65)  0.07 0.89 (0.57-1.39) 0.61
2 (TAA)  11 (5.1%)  73 (34.1%) 130 (60.7%)  15 (9.4%)  48 (30.0%)  97 (60.6%) 0.89 (0.64-1.24)  0.50 0.99 (0.65-1.51)  0.98 0.52 (0.23 - 1.17) 0.12
3 (TGA)   5 (2.3%)  65 (30.4%) 144 (67.3%)   6 (3.8%)  46 (28.8%) 108 (67.5%) 0.96 (0.66-1.40)  0.83 1.01 (0.65-1.56)  0.97 0.61 (0.18-2.05) 0.43
9 1 (GG)  70 (32.7%) 105 (49.1%)  39 (18 2%)  46 (28.8%)  83 (51.9%)  31 (19.4%) 1.11 (0.83-1.49)  0.48 1.08 (0.64-1.82)  0.78 1.20 (0.77-1.88) 0.41
2 (AA)  10 (4.7%)  72 (33.6%) 132 (61.7%)   8 (5.0%)  68 (42.5%)  84 (52.5%) 0.76 (0.54-1.08)  0.12 0.69 (0.45-1.04)  0.08 0.93 (0.36-2.42)0 . 8 8
3 (AG)  10 (4.7%)  71 (33.2%) 133 (62.1%)   5 (3.1%)  49 (30.6%) 106 (66.3%) 1.19 (0.83-1.72)  0.34 1.20 (0.78-1.84)  0.41 1.52 (0.51-4.54)0 . 4 5
10 1 (GGAAG)  60 (28.0%) 114 (53.3%)  40 (18.7%)  44 (27.5%)  87 (54.4%)  29 (18.1%) 1.00 (0.74-1.35)  1.0 0.96 (0.57-1.63)  0.89 1.03 (0.65-1.62) 0.91
2 (GGAAT)   6 (2.8%)  68 (31.8%) 140 (65.4%)   2 (1.3%)  37 (23.1%) 121 (75.6%) 1.59 (1.05-2.42)  0.029* 1.64 (1.04-2.59)  0.034* 2.28 (0.45-11.44) 0.32
3 (AAGAT)   2 (0.9%)  46 (21.5%) 166 (77.6%)   1 (0.6%)  43 (26.9%) 116 (72.5%) 0.79 (0.51-1.25)  0.32 0.76 (0.48-1.22)  0.26 1.50 (0.13-16.69) 0.74
4 (AGACT)   0 (0.0%)  38 (17.8%) 176 (82.2%)   2 (1.3%)  37 (23.1%) 121 (75.6%) 0.64 (0.40-1.05)  0.08 0.67 (0.41-1.11)  0.12 0.00 (0.00-) 1.00
14 1 (GCTGT)  40 (18.7%) 107 (50.0%)  67 (31.3%)  31 (19.4%)  79 (49.4%)  50 (31.3%) 0.98 (0.73-1.32)  0.92 1.00 (0.64-1.55)  0.99 0.96 (0.57-1.61) 0.87
2 (AATTT)  20 (9.3%)  87 (40.7%) 107 (50.0%)   7 (4.4%)  72 (45.0%)  81 (50.6%) 1.16 (0.83-1.61)  0.39 1.03 (0.68-1.54)  0.90 2.25 (0.93-5.47) 0.07
3 (GACTA)   9 (4.2%)  56 (26.2%) 149 (69.6%)   1 (0.6%)  40 (25.0%) 119 (74.4%) 1.38 (0.92-2.07)  0.12 1.27 (0.80-2.00)  0.31 6.98 (0.88-55.67) 0.07
　 4 (GATGT)   0 (0.0%)  24 (11.2%) 190 (88.8%)   0 (0.0%)  28 (17.5%) 132 (82.5%) 0.60 (0.33-1.07)  0.08 0.60 (0.33-1.07)  0.08 - -
Haplotype distributions are shown as number (%). Odds ratio (OR), 95% confidence interval (CI), and P-values were from logistic regression analyses with the codominant, 
dominant,  and  recessive  models  controlling  age  and  gender  as  covariates.  No,  number;  case,  overweight  and  obese  subjects; P ,  P-value
Table 4. Comparison of clinical characteristics according to the polymorphisms of PBX1 among the case and control group
　 g.+185219G>A 　 g.+191272A>C
Control Case
P
Control Case
P
　 GG
(n=86)
GA + AA
(n=74)
　 GG
(n=138)
GA + AA
(n=76)
　 AA
(n=118)
AC + CC
(n=42)
AA
(n=176)
AC + CC
(n=38)
Age (year)  43.7 ± 6.1  43.6 ± 6.2  45.0 ± 6.2  44.4 ± 6.8 0.343  43.7 ± 6.0  43.5 ± 6.6 　  44.9 ± 6.3  44.5 ± 6.6 0.379 
SBP (mmHg) 114.9 ± 16.1
a 115.9 ± 16.3
b 123.0 ± 16.0
a 126.0 ± 20.2
b < 0.001 116.6 ± 16.8
a 112.0 ± 13.9
b 123.8 ± 17.5
a 125.3 ± 18.1
b < 0.001
DBP (mmHg)  71.9 ± 11.3
a  71.9 ± 9.2
b  77.7 ± 10.8
a  78.1 ± 12.1
b < 0.001  72.7 ± 10.8
a  69.5 ± 8.8
b  77.9 ± 11.4
a  77.4 ± 10.7
b < 0.001
Fasting plasma 
glucose (mg/dl)
 90.6 ± 13.0  88.9 ± 9.6  93.6 ± 10.8  93.9 ± 20.0 0.410   90.1 ± 12.0  89.3 ± 10.3  93.3 ± 10.2  95.6 ± 27.3 0.035
HbA1c (%)   5.4 ± 0.5  5.3 ± 0.4   5.5 ± 0.6   5.5 ± 0.7 0.149   5.3 ± 0.4   5.3 ± 0.4   5.5 ± 0.6   5.5 ± 0.9 0.144
Triglyceride (mg/dl)  97.4 ± 65.7
a  97.6 ± 44.3
b 132.6 ± 71.0
a 154.2 ± 171.8
b < 0.001  97.2 ± 59.5
a  98.4 ± 48.5 140.6 ± 125.6
a 138.9 ± 66.6 0.001
Total cholesterol 
(mg/dl)
183.5 ± 29.0
a 189.8 ± 30.9 196.4 ± 32.2
a 198.5 ± 38.0 0.009 185.2 ± 29.3
a 189.8 ± 32.0 196.6 ± 34.6
a 200.0 ± 33.5 0.013
HDL-C (mg/dl)  54.3 ± 10.9
a,c  59.8 ± 14.9
b,c  49.4 ± 11.1
a  50.5 ± 11.7
b < 0.001   55.3 ± 11.9
a,c  61.3 ± 15.3
b,c  49.5 ± 11.1
a  51.4 ± 12.1
b < 0.001
LDL-C (mg/dl)  08.5 ± 28.9
a 110.5 ± 28.8 　 120.5 ± 29.4
a 117.2 ± 37.6 0.019 　 109.6 ± 28.7 108.7 ± 29.5 　 119.0 ± 32.9 120.8 ± 30.8 0.025
Data  expressed  as  mean ± SD.
P  valves  represent  the  significance  of  difference  among  the  groups  using  one-way  analysis  of  variance.
Mean  values  followed  by  same  superscripts  within  column  are  significantly  different  at  P<0.05  by  Tukey’s  test.
SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; 
n,  number;  P,  P-value;  case,  overweight  and  obese  subjects
OR=1.59, 95% CI=1.05-2.42) and recessive (P=0.034, OR=1.64, 
95% CI=1.04-2.59) models. However, when Bonferroni’s 
correction for the multiple comparisons was strictly applied, no 
haplotype also remained significant in terms of the association 
with obesity.
For the association analysis of obesity-related phenotypes, we 
assessed whether the obesity-related phenotypes differed between 
the two groups (case and control) according to the PBX1 
polymorphisms. There were significant differences in SBP, DBP, 
TG, total cholesterol, HDL-C, and LDL-C, except fasting plasma 
glucose and HbA1c, between the control and case group for the 
g.+185219G>A and g.+191272A>C (Table 4). In the control Ju Yeon Ban et al. 293
group, subjects that carried the minor allele had higher 
HDL-cholesterol level compared to the homozygote for the major 
allele for both g.+185219G>A and g.+191272A>C (59.8 ± 14.9 
vs 54.3 ± 10.9 and 61.3 ± 15.3 vs 55.3 ± 11.9, respectively, 
P<0.001). As shown in Table 1, HDL-cholesterol level was 
significantly lower in the case group compared to the control 
group (49.8 ± 11.3 vs 56.9 ± 13.1, P<0.001). Therefore, these 
results suggest that the association between the homozygote for 
the major allele for both g.+185219G>A and g.+191272A>C and 
HDL-C was attributable to an increased risk of obesity.
Discussion
Obesity is a common complex disease that involves multiple 
genetic variants interacting with environmental and behavioral 
factors, and is associated with an increased risk of developing 
insulin resistance and type 2 diabetes. PBX1 gene, comprised 
of nine exons spanning over 285 kb, maps to a region of 
chromosome 1 that shows well-replicated linkage to type 2 
diabetes in multiple ethnic groups. Several studies support an 
association between PBX1 polymorphisms and type 2 diabetes 
mellitus
  (Elbein et al., 1999; McCarthy, 2003; Ng et al., 2004; 
Thameem  et al., 2001; Xiang et al., 2004). In this study, we 
evaluated the gene as a possible candidate gene for obesity based 
on the close relationship between obesity and type 2 diabetes. 
Our results suggest that some SNPs in the PBX1 gene contribute to 
obesity and metabolic alterations in a Korean population. In a 
case-control analysis, of the 66 SNPs examined in PBX1, seven 
SNPs (g.+75186C>T, g.+78350C>A, g.+80646C>T, g.+138004C 
>T, g.+185219G>A, g.+191272A>C, and g.+265317T>A) were 
significantly associated with the risk of obesity. Moreover, 
haplotypes 1 (CAC) and 3 (TAC) of block 3, consisted of 
g.+80646C>T, g.+87440A>G, and g.+91850C>T, and haplotype 
2 (GGAAT) of block 10, comprised of g.+185286G>A, g.+ 
185602G>A, g.+191125A>G, g.+191272A>C, and g.+194899G 
>T, of the PBX1 gene had a significant association with the risk 
of obesity. To our best knowledge, this is the first demonstration 
that PBX1 polymorphisms are associated with susceptibility to 
obesity.
Interestingly, a strong association was also found between 
some SNPs and the HDL-C level in the control group. Control 
subjects that possessed minor allele g.+185219G>A and 
g.+191272A>C had higher HDL-C levels. Therefore, the minor 
allele g.+185219G>A and g.+191272A>C may decrease the risk 
of obesity. Recently, although there were many reports about 
individual gene polymorphisms on HDL-C levels
  (Chien et al., 
2008; Kitjaroentham et al., 2007), to our knowledge, this is the 
first report on the association between PBX1 polymorphisms and 
HDL-C levels.
We uncovered several intriguing associations between the 
PBX1 polymorphisms and obesity and related alterations. 
Nevertheless, our study has several limitations. First, many gene 
variants contribute to obesity and related alterations and those 
in PBX1 may have modest effects, requiring large sample sizes 
to detect associations
  (Hirschhorn & Daly, 2005). Our sample 
size was small, and it is possible that the associations that we 
observed between PBX1 SNPs and obesity could represent false 
positives. In our study, the power of the sample size was 
calculated using a genetic power calculator. Our sample provides 
the power more than 80% to detect more than 1.7-fold increased 
risk assuming an α-level of 0.05. Thus, our case-control study 
was sufficiently powerful to determine a positive association. 
Second, all SNPs selected in PBX1 are located in introns and 
do not cause an amino acid change. According to the dsSNP 
database (http://www.ncbi.nlm.nih.gov/SNP/) and the HapMap 
database (http://www.hapmap.org/), five SNPs in exons of PBX1 
gene were reported, but there are unknowns about heterozygosity 
of them. For this reason, we excluded SNPs present in exons 
in our study. We suggest that significant polymorphisms in 
introns may be a marker rather than a direct contributor to the 
genetic functions. The effects of other genetic variations linked 
to these polymorphisms may have functional significance. 
However, we cannot exclude a possibility that these intronic 
polymorphisms have a role on its genetic function via the change 
of alternative splicing
  (Ast, 2004). 
In conclusion, our findings suggest that polymorphisms in 
PBX1 gene might be one of the genetic factors for the risk of 
obesity, especially in association with alteration of HDL-C level, 
in a Korean population. Further studies are needed to explore 
the specific association between g.+185219G>A and g.+ 
191272A> and HDL-C.
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